Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px
Document › Details

Confo Therapeutics N.V.. (12/19/17). "Press Release: Confo Therapeutics Enters into Drug Discovery Collaboration with Roche". Ghent.

Region Region ALL
Organisation Organisation Roche (Group)
Products Product drug discovery services
  Product 2 GPCR agonist
Index term Index term Roche–Confo Therapeutics: drug discovery services, 201712–202005 collab up to €87.5m plus milestones r+d + commerc small molecule GPCR agonists
Person Person Ververken, Cedric (Confo Therapeutics 201610– CEO before Ablynx)
     


Confo Therapeutics, an emerging drug discovery company, announced today that it has entered into a research collaboration and license agreement with Roche for the discovery, development and commercialisation of novel, small molecule agonists of an undisclosed G-protein coupled receptor (GPCR) for the treatment of neurological and developmental disorders.

Under the terms of the agreement, Roche gains exclusive rights to the compounds resulting from the collaboration and will be responsible for their development, manufacturing and commercialisation. The financial terms include an upfront payment, pre-clinical milestones and research funding to Confo Therapeutics totaling €6 million over the initial 30 months period of the collaboration. In addition, Confo Therapeutics is eligible to receive up to €81.5 million of payments for certain development, regulatory and commercial milestones, plus tiered royalties on the annual net sales of any products resulting from the collaboration.

“Securing this partnership with Roche is another significant corporate milestone for Confo Therapeutics,” said Dr. Cedric Ververken, CEO. “The decision by a global pharmaceutical company to work with Confo Therapeutics further validates the strength of our proprietary Confo technology and the capabilities of our team. It also strengthens our resolve to vigorously pursue our own proprietary product pipeline in addition to enabling our partners to develop valuable medicines for patients.”


More information:
Email: info@confotherapeutics.com
www.confotherapeutics.com


About Confo Therapeutics

Confo Therapeutics is a VUB-VIB spin-off co-founded in 2015 by VIB and Capricorn Venture Partners with the support of MINTS, PMV, QBIC and V-Bio Ventures. Confo Therapeutics is a drug discovery company building a portfolio of first-in-class programs based on its proprietary Confo® technology, using antibody fragments or “Confobodies” to lock inherently unstable functional conformations of GPCRs as a superior starting point for drug discovery.

G-protein coupled receptors (GPCRs) are attractive drug targets in the treatment of many different conditions, playing an essential part in numerous life processes and influencing diseases. GPCRs are flexible signaling switches located in the cell membrane and pass outside signals into the cell through conformational changes.

More info: www.confotherapeutics.com

   
Record changed: 2018-01-08

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Confo Therapeutics N.V.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px




» top